Neuroendocrine tumors (NENs) are a group of neuroendocrine cell tumors that originate from the uptake and decarboxylation of amine precursors. nENs can occur in different parts of the body, including the gastrointestinal tract, pancreas, liver, bile, bronchus, lung, adrenal gland, paraganglia, thyroid, etc., among which the gastrointestinal tract is the most common. Previously, NENs were considered to be a relatively rare tumor, but epidemiological studies have shown that the current incidence of gastrointestinal NENs has increased 5-fold compared to 30 years ago, and the annual incidence of gastric neuroendocrine neoplasms (gNENs) is 0.3/100,000, accounting for about 6% of all NENs. The results of long-term follow-up studies suggest that NENs are all likely to have malignant potential, but the factors affecting the prognosis of NENs are unclear. In this study, we retrospectively analyzed the clinicopathological data of 80 patients with gNENs admitted to Zhongshan Hospital of Fudan University from January 2002 to December 2011, and analyzed the clinicopathological features and treatment modalities of gNENs to investigate the clinicopathological features, treatment modalities and factors affecting the prognosis of gastric neuroendocrine tumors (gNENs). The clinical data of 80 patients with gNENs admitted to Zhongshan Hospital of Fudan University from January 2002 to December 2011 were retrospectively analyzed. The patients all underwent gastroscopic biopsy. For gNENs with biopsy results suggesting good differentiation and ≤2 cm in diameter, endoscopic mucosal resection or endoscopic mucosal dissection was performed; for gNENs with biopsy results suggesting poor differentiation and >2 cm in diameter, surgical resection was performed, and different procedures were selected according to the location of the tumor. Follow-up was performed by a combination of telephone, letter and outpatient review. The follow-up period was up to October 31, 2013. The KaplanMeier method was used to plot survival curves and calculate survival rates, and the Logrank test was used for single-factor analysis and the COX proportional risk regression model was used for multi-factor analysis. Eighty patients with gNENs clinically presented with pain and discomfort in the supra-abdominal region in 58 cases. Tumor sites: cardia in 32 cases, gastric body in 40 cases, pylorus in 8 cases; tumor gross typing: ulcerated type 44 polyp type in 25 cases, augmented type in 11 cases. The average diameter of tumor was 2.6 cm (0.4-7.5. Tumor grading: G1 grade 27 cases, G2 grade 10 cases, G3 grade 43 cases. The tumors did not metastasize in 45 cases, with lymph node metastasis in 34 cases (distant metastasis in 2 cases), and only with distant metastasis in 1 case. 31 patients with gastric neuroendocrine tumors underwent endoscopic resection, and none of them received adjuvant chemotherapy after surgery. 49 patients (6 cases of gastric neuroendocrine tumors and 43 cases of gastric neuroendocrine carcinoma) underwent radical resection, including 16 cases of proximal major gastrectomy, 15 cases of distal major gastrectomy, and 15 cases of total gastrectomy. Seventy-nine patients were followed up with a median follow-up time of 42.0 months (2.0 to 113.0 months). The mean survival time of patients was 75.6 months (2.8 to 100.8 months), and the overall survival rates at 1, 3, and 5 years were 91.3%, 75.8%, and 66.5%, respectively. 5-year survival rates were 100.0%, 100.0%, and 38.0% for patients with G1, G2, and G3 grades, respectively. The results of univariate analysis showed that gender, treatment modality, postoperative chemotherapy, tumor bulk type, tumor diameter, tumor grading, and tumor stage were related to patients’ prognosis Clinical manifestations were mostly nonspecific, with pain and discomfort in the supra-abdominal region dominating, and the tumor sites were mostly in the cardia and gastric body, and the grading and stage of gNENs were highly variable. Endoscopic or surgical resection is the main treatment for gNENs. The prognosis is related to the gender of the patient, and female patients have a better prognosis.